Builds on Global Intellectual Property Portfolio to Protect DNAbilize® PlatformHOUSTON, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its ...

First Solid Tumor Patient Treated with Second, Higher Dose in Phase 1/1b BP1001-A Clinical Trial Experienced Tumor Reduction and Continued Stable Disease Reports Continued Patient Progress from Phase ...

DeepSeek has rattled the AI industry. Here’s a quick look at other Chinese AI models ...

Cure Rare Disease (CRD) announced it has been awarded a $5.69 million grant from the California Institute for Regenerative Medicine (CIRM) to advance the development of an antisense oligonucleotide ...

Equities research analysts at StockNews.com assumed coverage on shares of Bio-Path (NASDAQ:BPTH – Get Free Report) in a report released on Wednesday. The firm set a “sell” rating on the stock.

PORTLAND, IN, UNITED STATES, January 28, 2025 /EINPresswire / -- The RNA based therapeutics has been explored as a promising treatment option for the diseases which are difficult to treat. Development ...

Faculty of Pharmaceutical Sciences, Tohoku Medical and Pharmaceutical University, Komatsushima 4-4-1, Aoba-ku, Sendai 981-8558, Japan ...

New research published in the Journal of Chromatography A examines the effect of flow rate on plate height and resolution for antisense oligonucleotides (ONs) under hydrophilic interaction liquid ...

Commissions do not affect our editors' opinions or evaluations. Over the past 10 years, the technology sector has enjoyed stratospheric performance. You can’t even match the tech funds category ...

Wondering what topics we're covering? We put together a collection with articles from other Nature Portfolio journals to highlight some of the areas we plan to publish in.

From leveling the AI playing field to advancing drone technology and medical diagnostics via wearables, 2025 will deliver new, efficient computer science-based solutions for consumers and businesses ...